Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Apr;38(4):861–864. doi: 10.1128/aac.38.4.861

Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.

J M Gobert 1, K M Remington 1, Y Q Zhu 1, T W North 1
PMCID: PMC284556  PMID: 8031060

Abstract

Mutants of feline immunodeficiency virus (FIV) were selected in cell culture in the continuous presence of 10 microM (each) 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxyinosine (ddI). These mutants (AIR-1 and AIR-3) displayed a 13-fold resistance to AZT but had less than a 2-fold decrease in susceptibility to ddI. Interestingly, the AIR mutants were cross-resistant to phosphonoformate (PFA) and were hypersensitive to 2',3'-dideoxycytidine (ddC). Mutants of FIV were also selected in the presence of 10 microM ddI alone (DIS-1, DIS-2c), and these displayed a two- to fourfold decrease in susceptibility to ddI. Like the mutants selected with the combination of AZT plus ddI, DIS-1 and DIS-2c were cross-resistant to PFA and were hypersensitive to ddC. However, they remained as susceptible as wild-type FIV to AZT. Thus, the mutants selected with the combination of AZT plus ddI have phenotypes which reflect those obtained by selection with these drugs individually.

Full text

PDF
861

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackley C. D., Yamamoto J. K., Levy N., Pedersen N. C., Cooper M. D. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J Virol. 1990 Nov;64(11):5652–5655. doi: 10.1128/jvi.64.11.5652-5655.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barlough J. E., Ackley C. D., George J. W., Levy N., Acevedo R., Moore P. F., Rideout B. A., Cooper M. D., Pedersen N. C. Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infections. J Acquir Immune Defic Syndr. 1991;4(3):219–227. [PubMed] [Google Scholar]
  3. Barlough J. E., North T. W., Oxford C. L., Remington K. M., Dandekar S., Ellis M. N., Pedersen N. C. Feline immunodeficiency virus infection of cats as a model to test the effect of certain in vitro selection pressures on the infectivity and virulence of resultant lentivirus variants. Antiviral Res. 1993 Dec;22(4):259–272. doi: 10.1016/0166-3542(93)90036-i. [DOI] [PubMed] [Google Scholar]
  4. Cronn R. C., Remington K. M., Preston B. D., North T. W. Inhibition of reverse transcriptase from feline immunodeficiency virus by analogs of 2'-deoxyadenosine-5'-triphosphate. Biochem Pharmacol. 1992 Oct 6;44(7):1375–1381. doi: 10.1016/0006-2952(92)90539-u. [DOI] [PubMed] [Google Scholar]
  5. Eron J. J., Chow Y. K., Caliendo A. M., Videler J., Devore K. M., Cooley T. P., Liebman H. A., Kaplan J. C., Hirsch M. S., D'Aquila R. T. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob Agents Chemother. 1993 Jul;37(7):1480–1487. doi: 10.1128/aac.37.7.1480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gao Q., Gu Z. X., Parniak M. A., Li X. G., Wainberg M. A. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. J Virol. 1992 Jan;66(1):12–19. doi: 10.1128/jvi.66.1.12-19.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gao Q., Gu Z., Hiscott J., Dionne G., Wainberg M. A. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother. 1993 Jan;37(1):130–133. doi: 10.1128/aac.37.1.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ishida T., Tomoda I. Clinical staging of feline immunodeficiency virus infection. Nihon Juigaku Zasshi. 1990 Jun;52(3):645–648. doi: 10.1292/jvms1939.52.645. [DOI] [PubMed] [Google Scholar]
  9. North T. W., Cronn R. C., Remington K. M., Tandberg R. T. Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses. Antimicrob Agents Chemother. 1990 Aug;34(8):1505–1507. doi: 10.1128/aac.34.8.1505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. North T. W., Cronn R. C., Remington K. M., Tandberg R. T., Judd R. C. Characterization of reverse transcriptase from feline immunodeficiency virus. J Biol Chem. 1990 Mar 25;265(9):5121–5128. [PubMed] [Google Scholar]
  11. North T. W., North G. L., Pedersen N. C. Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother. 1989 Jun;33(6):915–919. doi: 10.1128/aac.33.6.915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Novotney C., English R. V., Housman J., Davidson M. G., Nasisse M. P., Jeng C. R., Davis W. C., Tompkins M. B. Lymphocyte population changes in cats naturally infected with feline immunodeficiency virus. AIDS. 1990 Dec;4(12):1213–1218. doi: 10.1097/00002030-199012000-00005. [DOI] [PubMed] [Google Scholar]
  13. Pedersen N. C., Barlough J. E. Clinical overview of feline immunodeficiency virus. J Am Vet Med Assoc. 1991 Nov 15;199(10):1298–1305. [PubMed] [Google Scholar]
  14. Pedersen N. C., Ho E. W., Brown M. L., Yamamoto J. K. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science. 1987 Feb 13;235(4790):790–793. doi: 10.1126/science.3643650. [DOI] [PubMed] [Google Scholar]
  15. Remington K. M., Chesebro B., Wehrly K., Pedersen N. C., North T. W. Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J Virol. 1991 Jan;65(1):308–312. doi: 10.1128/jvi.65.1.308-312.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Remington K. M., Zhu Y. Q., Phillips T. R., North T. W. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase. J Virol. 1994 Feb;68(2):632–637. doi: 10.1128/jvi.68.2.632-637.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. St Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M., Kellam P., Kemp S. D., Larder B. A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991 Sep 27;253(5027):1557–1559. doi: 10.1126/science.1716788. [DOI] [PubMed] [Google Scholar]
  18. Talbott R. L., Sparger E. E., Lovelace K. M., Fitch W. M., Pedersen N. C., Luciw P. A., Elder J. H. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5743–5747. doi: 10.1073/pnas.86.15.5743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Torten M., Franchini M., Barlough J. E., George J. W., Mozes E., Lutz H., Pedersen N. C. Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J Virol. 1991 May;65(5):2225–2230. doi: 10.1128/jvi.65.5.2225-2230.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Yamamoto J. K., Sparger E., Ho E. W., Andersen P. R., O'Connor T. P., Mandell C. P., Lowenstine L., Munn R., Pedersen N. C. Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res. 1988 Aug;49(8):1246–1258. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES